Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelcuityFRA:7VR 19 Cyclically Adjusted PB Ratio is 34.25 as of Jul. 17, 2026. GuruFocus rates FRA:7VR with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 697 Biotechnology companies, Celcuity ranks worse than 97.13% on this metric.
The historical rank and industry rank for Celcuity's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:7VR'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 26.57
Current: 26.57
During the past years, Celcuity's highest Cyclically Adjusted PB Ratio was 26.57. The lowest was 0.00. And the median was 0.00.
FRA:7VR's Cyclically Adjusted PB Ratio is ranked worse than 97.13% of 697
companies
in the Biotechnology industry
Industry Median: 1.62
vs FRA:7VR: 26.57
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Celcuity's adjusted book value per share data for the three months ended in Mar. 2026 was €0.958. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.73 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Celcuity (FRA:7VR) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Celcuity Cyclically Adjusted PB Ratio Related Terms
Celcuity Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Celcuity's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7VR vs ERAS, TNGX, DNTH: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Celcuity's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celcuity Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celcuity's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Celcuity's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Celcuity's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 34.25 mean?
Celcuity (FRA:7VR) has a Cyclically Adjusted PB Ratio of 34.25 as of Jul. 17, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Celcuity and its competitors. According to the industry distribution chart, Celcuity ranks #677 out of 697 companies in the Biotechnology industry, placing it in the top 97.1%.
Is Celcuity's Cyclically Adjusted PB Ratio too high?
Celcuity's current Cyclically Adjusted PB Ratio is 34.25. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.62. Celcuity's value of 34.25 is 2014.2% above this industry median. Based on the distribution chart, Celcuity ranks #677 out of 697 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celcuity has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's Cyclically Adjusted PB Ratio compare to ERAS and TNGX?
According to the Biotechnology industry distribution chart, Celcuity ranks #677 out of 697 companies for Cyclically Adjusted PB Ratio. This places Celcuity in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.62. Celcuity's value of 34.25 is 2014.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.62, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celcuity's current Cyclically Adjusted PB Ratio of 34.25 is 2014.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Celcuity and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celcuity's current Cyclically Adjusted PB Ratio is 34.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current Cyclically Adjusted PB Ratio of 34.25. The current Cyclically Adjusted PB Ratio is 34.25 and 2014.2% above the Biotechnology industry median of 1.62. Celcuity's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current Cyclically Adjusted PB Ratio is 34.25 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
19GF Score
Get the complete analysis for FRA:7VR
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VR has been successfully added to your 
